Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

Aside from their success for type 2 diabetes and overweight/obesity ... In the study – which was sponsored by drugmaker Eli Lilly – over 800 participants underwent 12 weeks of intensive lifestyle ...

Those at risk include people living with type 2 diabetes or high blood pr Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing ...

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus. Here's why they view Eli Lilly (NYSE ...

Eli Lilly and Company discovers ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more The best sheets make your bed a cozy, dreamy oasis — they're comfortable, well-fitting and don't ...

Fortune’s Term Sheet newsletter covers the latest news, insights, and analysis on private equity, venture capital, start-ups, mergers and acquisitions, high-value deals, and the dealmakers ...